Zealand Pharma

Zealand Pharma is a Danish biotechnology company engaged in the discovery, design and development of peptide-based medicines, with a particular focus on metabolic diseases. Its work spans peptide drug discovery and design, metabolic disease research, clinical development and broader pharmaceutical R&D. The company has advanced more than ten drug candidates through research, and its clinical pipeline of peptide-based medicines emphasises obesity and metabolic health.

The company is publicly traded on Nasdaq under the ticker ZEAL. Research and development is conducted from three locations: Copenhagen, Denmark, where the company is headquartered, and Boston and Cambridge, Massachusetts, in the United States. The Cambridge site houses newer research units, part of a broader expansion of the company's R&D footprint.

Zealand Pharma states a commitment to creating therapeutics for patients living with metabolic diseases and to building deep scientific expertise in peptide drug development.